收藏切换
Comparative efficacy and cost analysis of desvenlafaxine succinate and toludesvenlafaxine hydrochloride in the treatment of major depressive disorder
收藏切换
Hong-nan ZHANG, Zhi-yun HUANG, Bin-liang TONG, Hong-tao LIU*
Chinese Journal of New Drugs | 2026, 35(15) : 1675 - 1680
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(15): 1675-1680
Comparative efficacy and cost analysis of desvenlafaxine succinate and toludesvenlafaxine hydrochloride in the treatment of major depressive disorder
Full
Hong-nan ZHANG, Zhi-yun HUANG, Bin-liang TONG, Hong-tao LIU*
Affiliations
  • The First Hospital of Hebei Medical University, Shijiazhuang 050023, China
Published: 2026-08-15 doi: 10.20251/j.cnki.1003-3734.2026.15.014
Outline
收藏切换
Objective:

To compare the clinical efficacy and cost-effectiveness of desvenlafaxine succinate (DVS) and toludesvenlafaxine hydrochloride (TDVH) in the treatment of major depressive disorder (MDD) using the matching-adjusted indirect comparison (MAIC) method.

Methods:

Based on a multicenter, randomized, double-blind, positive-controlled clinical trial, data from 177 DVS patients were included and compared with the publicly available summary data from the TDVH Phase Ⅲ trial. MAIC was used to perform weighted matching on baseline characteristics, and changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17), Hamilton Anxiety Rating Scale (HAMA), and Clinical Global Impression-Severity Scale (CGI-S) scores were compared between the two groups. The total treatment cost and cost per unit improvement were calculated.

Results:

The improvement rates in HAMD-17, HAMA, and CGI-S scores were 66.1%, 50.6%, and 57.3% in the DVS group, compared with 59.8%, 58.1%, and 49.0%, respectively, in the TDVH group. Both the total treatment cost and the cost per unit improvement were lower for DVS than those for TDVH.

Conclusion:

DVS demonstrated advantages in efficacy and cost-effectiveness, indicating greater economic accessibility and providing a reference for drug selection and reimbursement decision-making in MDD treatment.

desvenlafaxine succinate  /  toludesvenlafaxine hydrochloride  /  major depressive disorder  /  matching-adjusted indirect comparison  /  cost-effectiveness ratio
张红楠, 黄志云, 佟彬良, 刘洪涛. 琥珀酸地文拉法辛与盐酸托鲁地文拉法辛在重性抑郁障碍治疗中的疗效与成本比较. 中国新药杂志, 2026 , 35 (15) : 1675 -1680 . DOI: 10.20251/j.cnki.1003-3734.2026.15.014
Hong-nan ZHANG, Zhi-yun HUANG, Bin-liang TONG, Hong-tao LIU. Comparative efficacy and cost analysis of desvenlafaxine succinate and toludesvenlafaxine hydrochloride in the treatment of major depressive disorder[J]. Chinese Journal of New Drugs, 2026 , 35 (15) : 1675 -1680 . DOI: 10.20251/j.cnki.1003-3734.2026.15.014
Year 2026 volume 35 Issue 15
59
7
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.15.014
  • Online Date:2026-10-26
  • Published:2026-08-15
Article Data
Affiliations
History
  • Accepted:2026-03-19
Funding
Affiliations
    The First Hospital of Hebei Medical University, Shijiazhuang 050023, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.15.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT